Akero Therapeutics is a biotechnology business based in the US. Akero Therapeutics shares (AKRO) are listed on the NASDAQ and all prices are listed in US Dollars. Akero Therapeutics employs 58 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $28.32 |
|---|---|
| 52-week range | $11.25 - $53.77 |
| 50-day moving average | $22.26 |
| 200-day moving average | $21.22 |
| Wall St. target price | $45.78 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-3.24 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $28.32 from 2024-07-25
| 1 week (2024-07-19) | 5.83% |
|---|---|
| 1 month (2024-06-26) | 23.51% |
| 3 months (2024-04-26) | 43.47% |
| 6 months (2024-01-26) | 28.03% |
| 1 year (2023-07-26) | -32.09% |
|---|---|
| 2 years (2022-07-26) | 169.20% |
| 3 years (2021-07-26) | 30.09% |
| 5 years (2019-07-26) | 8.42% |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -20.23% |
| Return on equity TTM | -31.11% |
| Profit margin | 0% |
| Book value | $12.24 |
| Market Capitalization | $1.9 billion |
TTM: trailing 12 months
We're not expecting Akero Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Akero Therapeutics's shares have ranged in value from as little as $11.25 up to $53.77. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akero Therapeutics's is -0.282. This would suggest that Akero Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Akero Therapeutics has bucked the trend.
Akero Therapeutics, Inc. , together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc.
Steps to owning and managing ZTEK, with 24-hour and historical pricing before you buy.
Steps to owning and managing MYNZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing ATAI, with 24-hour and historical pricing before you buy.
Steps to owning and managing OWLT, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing HUM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ILMN, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.